Updates are available Correction dated 2024-11-09
Click to view Correction: https://doi.org/10.1007/s00520-024-08988-0
-
Authors
Hong, Catherine
Jensen, Siri Beier
Vissink, Arjan
Bonomo, Pierluigi
Santos-Silva, Alan Roger
Gueiros, Luiz Alcino
Epstein, Joel B.
Elad, Sharon
- License Information
-
More Information
Article History
Received: 7 June 2024
Accepted: 24 June 2024
First Online: 25 July 2024
Change Date: 9 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00520-024-08988-0
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: C. Hong, S. Beier Jensen, A. Vissink, A.R. Santos-Silva, L.A. Gueiros, S. Elad reported no relevant financial or non-financial interests to disclose. P. Bonomo reports personal fees from Merck & Co., Inc, Merck Sharpe & Dohme and Pfizer Inc. J.B. Epstein is a consultant for Galera Therapeutics, Janssen, Biopharmaceuticals, Nestle Healthcare, Tosk Inc. J.B. Epstein is a consultant and has funded research from SaNOtize Research and Development Corp. J.B. Epstein is Associate Editor-in-Chief for Supportive Care in Cancer.
: The MASCC/ISOO OCSG statements have been developed to facilitate expert-opinion-based management of oral complications of cancer itself and cancer therapy, where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. Statement authors and the MASCC/ISOO do not guarantee or take responsibility for the clinical outcomes in individual patients.
